{"id":75143,"date":"2026-09-22T21:21:53","date_gmt":"2026-09-22T21:21:53","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=75143"},"modified":"2026-09-23T04:12:58","modified_gmt":"2026-09-23T04:12:58","slug":"american-analyst-updates-sept-22nd-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/","title":{"rendered":"American Analyst Updates: Sept 22nd, 2026"},"content":{"rendered":"

<\/p>\n

<\/p>\n

<\/p>\n

Analyst Ratings (USA)<\/a><\/h2>\n

The current analyst outlook remains cautiously positive, with positive recommendations accounting for most of today\u2019s coverage and upgrades continuing to outnumber downgrades. However, price-target reductions exceeded increases, indicating that analysts are becoming more disciplined about valuations and near-term earnings expectations. Technology, healthcare and biotechnology continue to attract the strongest interest, while energy, financial and consumer stocks show a more mixed outlook. Overall, sentiment remains constructive, but analysts are increasingly favouring companies with clear earnings momentum, strong balance sheets and reliable growth prospects.<\/p>\n

Wall Street analysts released 199 rating and price-target actions covering 160 U.S.-listed companies on September 22, 2026. The daily activity included 11 upgrades, 5 downgrades, 32 target increases, 38 target reductions, 34 new coverage initiations, 12 newly stated price targets and 67 reiterated ratings.<\/p>\n

199 Analyst Updates<\/h2>\n

Abivax (ABVX)<\/strong>: Barclays maintained its Overweight rating with a US$148.00 price target.<\/p>\n

Abivax (ABVX)<\/strong>: Truist Financial lowered its price target to US$151.00 from US$155.00 while retaining a Buy rating.<\/p>\n

Abivax (ABVX)<\/strong>: Wedbush lowered its price target to US$118.00 from US$140.00 while retaining a Neutral rating.<\/p>\n

Adaptive Biotechnologies (ADPT)<\/strong>: BTIG raised its price target to US$34.00 from US$25.00 while retaining a Buy rating.<\/p>\n

Adaptive Biotechnologies (ADPT)<\/strong>: National Bank Financial set a US$34.00 price target.<\/p>\n

Advanced Energy Industries (AEIS)<\/strong>: Cantor Fitzgerald maintained its Overweight rating.<\/p>\n

Alaska Air Group (ALK)<\/strong>: UBS maintained its Buy rating and raised its price target to US$54.00 from US$52.00.<\/p>\n

Alcoa (AA)<\/strong>: Freedom Broker raised its price target to US$76.00 from US$64.00 while retaining a Buy rating.<\/p>\n

Alkermes (ALKS)<\/strong>: Robert W. Baird raised its price target to US$61.00 from US$58.00 while retaining an Outperform rating.<\/p>\n

Alkermes (ALKS)<\/strong>: RBC Capital Markets maintained its Outperform rating with a US$56.00 price target.<\/p>\n

Allegion (ALLE)<\/strong>: Evercore maintained its Outperform rating with a US$180.00 price target.<\/p>\n

Amphenol (APH)<\/strong>: BNP Paribas Exane raised its price target to US$110.00 from US$107.50 while retaining an Outperform rating.<\/p>\n

Amrize (AMRZ)<\/strong>: UBS lowered its price target to US$42.00 from US$57.00 while retaining a Neutral rating.<\/p>\n

AnaptysBio (ANAB)<\/strong>: Cantor Fitzgerald maintained its Overweight rating.<\/p>\n

AnaptysBio (ANAB)<\/strong>: HC Wainwright maintained its Buy rating with a US$95.00 price target.<\/p>\n

Anixa Biosciences (ANIX)<\/strong>: HC Wainwright lowered its price target to US$6.00 from US$7.00 while retaining a Buy rating.<\/p>\n

Antero Midstream (AM)<\/strong>: Capital One Financial upgraded the stock to Overweight and set a US$25.00 price target.<\/p>\n

ArriVent BioPharma (AVBP)<\/strong>: Cantor Fitzgerald maintained its Overweight rating.<\/p>\n

Atlanticus (ATLC)<\/strong>: BTIG maintained its Buy rating with a US$179.00 price target.<\/p>\n

AvePoint (AVPT)<\/strong>: Cantor Fitzgerald maintained its Overweight rating.<\/p>\n

BankUnited (BKU)<\/strong>: Citigroup maintained its Sell rating.<\/p>\n

Bicara Therapeutics (BCAX)<\/strong>: HSBC downgraded the stock to Equal Weight.<\/p>\n

Bilibili (BILI)<\/strong>: BNP Paribas Exane initiated coverage with an Outperform rating and a US$23.00 price target.<\/p>\n

BitMine Immersion Technologies (BMNR)<\/strong>: B. Riley raised its price target to US$34.00 from US$30.00 while retaining a Buy rating.<\/p>\n

Brinker International (EAT)<\/strong>: Northcoast Research upgraded the stock to Buy and set a US$275.00 price target.<\/p>\n

Butterfly Network (BFLY)<\/strong>: Needham initiated coverage with a Buy rating and a US$10.00 price target.<\/p>\n

Cal-Maine Foods (CALM)<\/strong>: Stephens set a US$80.00 price target with an Equal Weight rating, compared with a previous target of US$90.00.<\/p>\n

Camtek (CAMT)<\/strong>: Cantor Fitzgerald maintained its Neutral rating with a US$175.00 price target.<\/p>\n

Capri (CPRI)<\/strong>: Jefferies maintained its Hold rating.<\/p>\n

Carnival (CCL)<\/strong>: Deutsche Bank set a US$32.00 price target.<\/p>\n

Carnival (CCL)<\/strong>: TD Cowen lowered its price target to US$32.00 from US$34.00 while retaining a Buy rating.<\/p>\n

Celldex Therapeutics (CLDX)<\/strong>: Cantor Fitzgerald raised its price target to US$72.00 from US$61.00 while retaining an Overweight rating.<\/p>\n

Celldex Therapeutics (CLDX)<\/strong>: HC Wainwright raised its price target to US$64.00 from US$42.00 while retaining a Buy rating.<\/p>\n

Celldex Therapeutics (CLDX)<\/strong>: Stifel Nicolaus set a US$68.00 price target.<\/p>\n

ChargePoint (CHPT)<\/strong>: UBS maintained its Neutral rating and raised its price target to US$9.00 from US$8.00.<\/p>\n

Chord Energy (CHRD)<\/strong>: UBS lowered its price target to US$184.00 from US$189.00 while retaining a Buy rating.<\/p>\n

Cintas (CTAS)<\/strong>: Citigroup maintained its Sell rating and raised its price target to US$180.00 from US$175.00.<\/p>\n

Cisco Systems (CSCO)<\/strong>: Piper Sandler lowered its price target to US$125.00 from US$132.00 while retaining a Neutral rating.<\/p>\n

Coinbase Global (COIN)<\/strong>: William Blair maintained its Outperform rating.<\/p>\n

Columbia Banking System (COLB)<\/strong>: Citigroup lowered its price target to US$31.00 from US$32.00 while retaining a Neutral rating.<\/p>\n

Connect Biopharma (CNTB)<\/strong>: Oppenheimer lowered its price target to US$5.00 while retaining an Outperform rating.<\/p>\n

Constellation Brands (STZ)<\/strong>: Barclays lowered its price target to US$122.00 from US$132.00 while retaining an Equal Weight rating.<\/p>\n

Constellation Brands (STZ)<\/strong>: Citigroup lowered its price target to US$165.00 from US$185.00 while retaining a Buy rating.<\/p>\n

Costco Wholesale (COST)<\/strong>: Evercore maintained its Outperform rating.<\/p>\n

Crane NXT (CXT)<\/strong>: Jefferies initiated coverage with a Buy rating and a US$60.00 price target.<\/p>\n

CRH (CRH)<\/strong>: UBS lowered its price target to US$135.00 from US$147.00 while retaining a Buy rating.<\/p>\n

CVRx (CVRX)<\/strong>: Canaccord Genuity set a US$5.00 price target.<\/p>\n

CVS Health (CVS)<\/strong>: UBS maintained its Buy rating.<\/p>\n

D.R. Horton (DHI)<\/strong>: BTIG maintained its Buy rating with a US$174.00 price target.<\/p>\n

D.R. Horton (DHI)<\/strong>: Keefe, Bruyette & Woods lowered its price target to US$160.00 from US$167.00 while retaining a Market Perform rating.<\/p>\n

Darling Ingredients (DAR)<\/strong>: UBS raised its price target to US$88.00 from US$78.00 while retaining a Buy rating.<\/p>\n

Deep Fission (FISN)<\/strong>: Roth Capital initiated coverage with a Buy rating and a US$18.00 price target.<\/p>\n

Driven Brands (DRVN)<\/strong>: Barclays initiated coverage with an Equal Weight rating and a US$14.00 price target.<\/p>\n

East West Bancorp (EWBC)<\/strong>: Citigroup lowered its price target to US$152.00 from US$156.00 while retaining a Buy rating.<\/p>\n

Eldorado Gold (EGO)<\/strong>: Bank of America upgraded the stock to Buy and raised its price target to US$54.00 from US$32.00.<\/p>\n

Elemental Royalty (ELE)<\/strong>: HC Wainwright lowered its price target to US$31.00 from US$33.00 while retaining a Buy rating.<\/p>\n

Eli Lilly and Company (LLY)<\/strong>: TD Cowen maintained its Buy rating with a US$1,250.00 price target.<\/p>\n

Endava (DAVA)<\/strong>: Deutsche Bank lowered its price target to US$2.00 from US$3.00 while retaining a Hold rating.<\/p>\n

Endava (DAVA)<\/strong>: TD Cowen maintained its Hold rating with a US$3.50 price target.<\/p>\n

Endava (DAVA)<\/strong>: William Blair downgraded the stock to Underperform.<\/p>\n

Energy Transfer (ET)<\/strong>: Capital One Financial initiated coverage with an Overweight rating and a US$26.00 price target.<\/p>\n

Energy Transfer (ET)<\/strong>: Melius Research initiated coverage with a Hold rating and a US$25.00 price target.<\/p>\n

Entera Bio (ENTX)<\/strong>: Cantor Fitzgerald initiated coverage with an Overweight rating.<\/p>\n

Enterprise Products Partners (EPD)<\/strong>: Capital One Financial initiated coverage with an Equal Weight rating and a US$42.00 price target.<\/p>\n

Enterprise Products Partners (EPD)<\/strong>: Melius Research initiated coverage with a Hold rating and a US$42.00 price target.<\/p>\n

Enterprise Products Partners (EPD)<\/strong>: RBC Capital Markets maintained its Outperform rating with a US$42.00 price target.<\/p>\n

Equifax (EFX)<\/strong>: Wells Fargo lowered its price target to US$200.00 from US$212.00 while retaining an Overweight rating.<\/p>\n

Ericsson (ERIC)<\/strong>: Morgan Stanley downgraded the stock to Underweight and lowered its price target to US$9.00 from US$11.00.<\/p>\n

Essent Group (ESNT)<\/strong>: BTIG initiated coverage with a Neutral rating.<\/p>\n

Everest Group (EG)<\/strong>: Rosenblatt Securities set a US$455.00 price target.<\/p>\n

Everest Group (EG)<\/strong>: RBC Capital Markets initiated coverage with an Outperform rating and a US$455.00 price target.<\/p>\n

Exelon (EXC)<\/strong>: Argus lowered its price target to US$49.00 from US$52.00 while retaining a Buy rating.<\/p>\n

Fair Isaac (FICO)<\/strong>: Wells Fargo lowered its price target to US$1,350.00 from US$1,450.00 while retaining an Overweight rating.<\/p>\n

Ferrovial (FER)<\/strong>: Morgan Stanley maintained its Overweight rating.<\/p>\n

Fifth Third Bancorp (FITB)<\/strong>: Citigroup upgraded the stock to Buy and raised its price target to US$62.00 from US$59.00.<\/p>\n

First Horizon (FHN)<\/strong>: Citigroup lowered its price target to US$28.00 from US$28.50 while retaining a Buy rating.<\/p>\n

First Solar (FSLR)<\/strong>: GLJ Research set a US$250.00 price target.<\/p>\n

FormFactor (FORM)<\/strong>: Cantor Fitzgerald maintained its Overweight rating.<\/p>\n

Forward Industries (FWDI)<\/strong>: B. Riley raised its price target to US$11.00 from US$9.00 while retaining a Buy rating.<\/p>\n

GE HealthCare Technologies (GEHC)<\/strong>: Needham initiated coverage with a Buy rating and a US$93.00 price target.<\/p>\n

Glaukos (GKOS)<\/strong>: Jefferies raised its price target to US$210.00 from US$190.00 while retaining a Buy rating.<\/p>\n

GRAIL (GRAL)<\/strong>: Robert W. Baird raised its price target to US$118.00 from US$96.00 while retaining an Outperform rating.<\/p>\n

Gulfport Energy (GPOR)<\/strong>: Pickering Energy Partners initiated coverage with an Outperform rating.<\/p>\n

Hancock Whitney (HWC)<\/strong>: Citigroup lowered its price target to US$86.00 from US$87.00 while retaining a Buy rating.<\/p>\n

HeartBeam (BEAT)<\/strong>: HC Wainwright downgraded the stock to Neutral.<\/p>\n

Heartflow (HTFL)<\/strong>: Canaccord Genuity raised its price target to US$56.00 from US$45.00 while retaining a Buy rating.<\/p>\n

Heritage Financial (HFWA)<\/strong>: Brean Capital upgraded the stock to Buy and set a US$33.00 price target.<\/p>\n

Heritage Financial (HFWA)<\/strong>: Capital One Financial set a US$33.00 price target.<\/p>\n

Hinge Health (HNGE)<\/strong>: Robert W. Baird raised its price target to US$90.00 from US$85.00 while retaining a Neutral rating.<\/p>\n

Hyperfine (HYPR)<\/strong>: BTIG maintained its Buy rating with a US$2.00 price target.<\/p>\n

IDEAYA Biosciences (IDYA)<\/strong>: Cantor Fitzgerald maintained its Overweight rating.<\/p>\n

Incyte (INCY)<\/strong>: RBC Capital Markets maintained its Sector Perform rating with a US$109.00 price target.<\/p>\n

Ionis Pharmaceuticals (IONS)<\/strong>: JPMorgan lowered its price target to US$70.00 from US$76.00 while retaining an Overweight rating.<\/p>\n

IonQ (IONQ)<\/strong>: Wedbush maintained its Outperform rating with a US$75.00 price target.<\/p>\n

iRadimed (IRMD)<\/strong>: Needham initiated coverage with a Hold rating.<\/p>\n

Johnson & Johnson (JNJ)<\/strong>: UBS maintained its Buy rating.<\/p>\n

KBR (KBR)<\/strong>: Oppenheimer lowered its price target to US$50.00 from US$60.00 while retaining an Outperform rating.<\/p>\n

KeyCorp (KEY)<\/strong>: Citigroup maintained its Neutral rating.<\/p>\n

Kinder Morgan (KMI)<\/strong>: Capital One Financial initiated coverage with an Equal Weight rating and a US$36.00 price target.<\/p>\n

Kinder Morgan (KMI)<\/strong>: Melius Research initiated coverage with a Buy rating and a US$38.00 price target.<\/p>\n

Kinder Morgan (KMI)<\/strong>: RBC Capital Markets raised its price target to US$36.00 from US$35.00 while retaining a Sector Perform rating.<\/p>\n

KindlyMD (NAKA)<\/strong>: B. Riley raised its price target to US$13.00 from US$11.00 while retaining a Buy rating.<\/p>\n

Kraft Heinz (KHC)<\/strong>: TD Cowen maintained its Hold rating with a US$22.00 price target.<\/p>\n

Kymera Therapeutics (KYMR)<\/strong>: Stifel Nicolaus raised its price target to US$152.00 from US$132.00 while retaining a Buy rating.<\/p>\n

Lennar (LEN)<\/strong>: Keefe, Bruyette & Woods lowered its price target to US$75.00 from US$85.00 while retaining an Underperform rating.<\/p>\n

Lexeo Therapeutics (LXEO)<\/strong>: Raymond James maintained its Strong Buy rating.<\/p>\n

Liftoff Mobile (LFTO)<\/strong>: Piper Sandler initiated coverage with a Neutral rating and a US$19.00 price target.<\/p>\n

Lipocine (LPCN)<\/strong>: Cantor Fitzgerald maintained its Overweight rating.<\/p>\n

Lithia Motors (LAD)<\/strong>: Citigroup lowered its price target to US$409.00 from US$455.00 while retaining a Buy rating.<\/p>\n

Maze Therapeutics (MAZE)<\/strong>: BTIG maintained its Buy rating with a US$46.00 price target.<\/p>\n

McGraw Hill (MH)<\/strong>: BTIG maintained its Buy rating with a US$17.00 price target.<\/p>\n

Meta Platforms (META)<\/strong>: Bank of America maintained its Buy rating with a US$810.00 price target.<\/p>\n

Meta Platforms (META)<\/strong>: Jefferies raised its price target to US$875.00 from US$710.00 while retaining a Buy rating.<\/p>\n

MetLife (MET)<\/strong>: Piper Sandler upgraded the stock to Overweight and raised its price target to US$110.00 from US$99.00.<\/p>\n

MGIC Investment (MTG)<\/strong>: BTIG initiated coverage with a Neutral rating.<\/p>\n

Microsoft (MSFT)<\/strong>: Oppenheimer raised its price target to US$570.00 from US$515.00 while retaining an Outperform rating.<\/p>\n

Moderna (MRNA)<\/strong>: UBS maintained its Neutral rating.<\/p>\n

Motorola Solutions (MSI)<\/strong>: Piper Sandler raised its price target to US$531.00 from US$530.00 while retaining an Overweight rating.<\/p>\n

NetEase (NTES)<\/strong>: BNP Paribas Exane initiated coverage with an Outperform rating and a US$180.00 price target.<\/p>\n

Netflix (NFLX)<\/strong>: BMO Capital Markets maintained its Outperform rating.<\/p>\n

Netflix (NFLX)<\/strong>: HSBC downgraded the stock to Hold and lowered its price target to US$76.00 from US$96.00.<\/p>\n

Nextpower (NXT)<\/strong>: Robert W. Baird lowered its price target to US$116.00 from US$156.00 while retaining an Outperform rating.<\/p>\n

NMI (NMIH)<\/strong>: BTIG initiated coverage with a Buy rating and a US$54.00 price target.<\/p>\n

NVR (NVR)<\/strong>: BTIG set a US$7,125.00 price target.<\/p>\n

Obsidian Therapeutics (OBX)<\/strong>: Leerink Partners initiated coverage with an Outperform rating and a US$32.00 price target.<\/p>\n

Okta (OKTA)<\/strong>: Robert W. Baird raised its price target to US$200.00 from US$185.00 while retaining an Outperform rating.<\/p>\n

Okta (OKTA)<\/strong>: Scotiabank raised its price target to US$190.00 from US$165.00 while retaining a Sector Outperform rating.<\/p>\n

Old National Bancorp (ONB)<\/strong>: Citigroup lowered its price target to US$30.00 from US$31.00 while retaining a Buy rating.<\/p>\n

Omeros (OMER)<\/strong>: Cantor Fitzgerald upgraded the stock to Overweight and set a US$22.00 price target.<\/p>\n

ON (ONON)<\/strong>: Goldman Sachs maintained its Buy rating.<\/p>\n

ONEOK (OKE)<\/strong>: Capital One Financial initiated coverage with an Overweight rating and a US$110.00 price target.<\/p>\n

Option Care Health (OPCH)<\/strong>: UBS maintained its Buy rating.<\/p>\n

Paramount Skydance (PSKY)<\/strong>: Citizens JMP maintained its Market Outperform rating with a US$14.00 price target.<\/p>\n

Paramount Skydance (PSKY)<\/strong>: Morgan Stanley raised its price target to US$11.50 from US$10.00 while retaining an Overweight rating.<\/p>\n

Pharming Group (PHAR)<\/strong>: HC Wainwright maintained its Buy rating with a US$37.00 price target.<\/p>\n

Pilgrim\u2019s Pride (PPC)<\/strong>: UBS maintained its Neutral rating.<\/p>\n

Popular (BPOP)<\/strong>: Citigroup lowered its price target to US$192.00 from US$200.00 while retaining a Buy rating.<\/p>\n

Priority Technology (PRTH)<\/strong>: Keefe, Bruyette & Woods raised its price target to US$8.00 from US$6.50 while retaining a Market Perform rating.<\/p>\n

Prosperity Bancshares (PB)<\/strong>: Citigroup lowered its price target to US$77.00 from US$79.00 while retaining a Neutral rating.<\/p>\n

PTC Therapeutics (PTCT)<\/strong>: Cantor Fitzgerald raised its price target to US$137.00 from US$130.00 while retaining an Overweight rating.<\/p>\n

Q2 (QTWO)<\/strong>: Piper Sandler maintained its Overweight rating with a US$82.00 price target.<\/p>\n

Quince Therapeutics (QNCX)<\/strong>: Citizens JMP upgraded the stock to Outperform and set a US$77.00 price target.<\/p>\n

Radian Group (RDN)<\/strong>: BTIG initiated coverage with a Buy rating and a US$48.00 price target.<\/p>\n

RadNet (RDNT)<\/strong>: Raymond James maintained its Strong Buy rating.<\/p>\n

Ralliant (RAL)<\/strong>: Evercore maintained its Outperform rating.<\/p>\n

Real Brokerage (REAX)<\/strong>: JonesTrading maintained its Buy rating with a US$40.00 price target.<\/p>\n

RenaissanceRe (RNR)<\/strong>: Jefferies upgraded the stock to Market Outperform.<\/p>\n

RenaissanceRe (RNR)<\/strong>: RBC Capital Markets initiated coverage with a Sector Perform rating and a US$365.00 price target.<\/p>\n

Rush Street Interactive (RSI)<\/strong>: Citigroup maintained its Market Outperform rating.<\/p>\n

Rush Street Interactive (RSI)<\/strong>: Citizens JMP maintained its Market Outperform rating with a US$34.00 price target.<\/p>\n

RxSight (RXST)<\/strong>: Bank of America lowered its price target to US$5.50 from US$6.50 while retaining an Underperform rating.<\/p>\n

RxSight (RXST)<\/strong>: Jefferies lowered its price target to US$5.75 from US$6.50 while retaining a Hold rating.<\/p>\n

Sandisk (SNDK)<\/strong>: Rosenblatt Securities initiated coverage with a Buy rating and a US$2,400.00 price target.<\/p>\n

SAP (SAP)<\/strong>: Citigroup maintained its Buy rating.<\/p>\n

SAP (SAP)<\/strong>: Jefferies maintained its Buy rating with a US$260.00 price target.<\/p>\n

Sharplink Gaming (SBET)<\/strong>: B. Riley maintained its Buy rating and raised its price target to US$14.00 from US$12.00.<\/p>\n

Sherwin-Williams (SHW)<\/strong>: RBC Capital Markets maintained its Outperform rating with a US$420.00 price target.<\/p>\n

SiriusPoint (SPNT)<\/strong>: RBC Capital Markets initiated coverage with an Outperform rating and a US$30.00 price target.<\/p>\n

Solana (HSDT)<\/strong>: B. Riley raised its price target to US$4.00 from US$3.50 while retaining a Buy rating.<\/p>\n

SoundHound AI (SOUN)<\/strong>: Piper Sandler lowered its price target to US$6.00 from US$7.00 while retaining a Neutral rating.<\/p>\n

STAAR Surgical (STAA)<\/strong>: Jefferies lowered its price target to US$23.00 from US$28.00 while retaining a Buy rating.<\/p>\n

Strategy (MSTR)<\/strong>: B. Riley raised its price target to US$195.00 from US$175.00 while retaining a Buy rating.<\/p>\n

Strive (ASST)<\/strong>: B. Riley raised its price target to US$33.00 from US$26.00 while retaining a Buy rating.<\/p>\n

Stryker (SYK)<\/strong>: TD Cowen lowered its price target to US$298.00 from US$355.00 while retaining a Hold rating.<\/p>\n

Summit Therapeutics (SMMT)<\/strong>: Cantor Fitzgerald maintained its Overweight rating.<\/p>\n

Terrestrial Energy (IMSR)<\/strong>: Roth Capital initiated coverage with a Buy rating and a US$15.00 price target.<\/p>\n

Texas Capital Bancshares (TCBI)<\/strong>: Citigroup lowered its price target to US$104.00 from US$107.00 while retaining a Neutral rating.<\/p>\n

Tiziana Life Sciences (TLSA)<\/strong>: BTIG maintained its Buy rating.<\/p>\n

Travere Therapeutics (TVTX)<\/strong>: HC Wainwright maintained its Buy rating with a US$67.00 price target.<\/p>\n

Travere Therapeutics (TVTX)<\/strong>: Wedbush maintained its Outperform rating with a US$76.00 price target.<\/p>\n

Turning Point Brands (TPB)<\/strong>: Oppenheimer lowered its price target to US$90.00 from US$130.00 while retaining an Outperform rating.<\/p>\n

Twilio (TWLO)<\/strong>: Rosenblatt Securities raised its price target to US$290.00 from US$275.00 while retaining a Buy rating.<\/p>\n

Twilio (TWLO)<\/strong>: TD Cowen raised its price target to US$300.00 from US$260.00 while retaining a Buy rating.<\/p>\n

Tyra Biosciences (TYRA)<\/strong>: HC Wainwright lowered its price target to US$29.00 from US$30.00 while retaining a Buy rating.<\/p>\n

Tyra Biosciences (TYRA)<\/strong>: Oppenheimer maintained its Outperform rating and lowered its price target to US$40.00 from US$50.00.<\/p>\n

U.S. Bancorp (USB)<\/strong>: Citigroup maintained its Buy rating.<\/p>\n

Upstart (UPST)<\/strong>: BTIG maintained its Buy rating with a US$43.00 price target.<\/p>\n

Valero Energy (VLO)<\/strong>: Jefferies downgraded the stock from Buy to Hold and set a US$401.00 price target.<\/p>\n

Vicor (VICR)<\/strong>: Needham maintained its Buy rating with a US$320.00 price target.<\/p>\n

Vicor (VICR)<\/strong>: Roth Capital maintained its Buy rating with a US$375.00 price target.<\/p>\n

Viking Therapeutics (VKTX)<\/strong>: HC Wainwright maintained its Buy rating.<\/p>\n

Viking Therapeutics (VKTX)<\/strong>: Morgan Stanley maintained its Overweight rating.<\/p>\n

Viking Therapeutics (VKTX)<\/strong>: Oppenheimer set a US$120.00 price target.<\/p>\n

Viridian Therapeutics (VRDN)<\/strong>: RBC Capital Markets raised its price target to US$38.00 from US$36.00 while retaining an Outperform rating.<\/p>\n

W.P. Carey (WPC)<\/strong>: Benchmark initiated coverage with a Buy rating.<\/p>\n

W.P. Carey (WPC)<\/strong>: Jefferies initiated coverage with a Buy rating and a US$73.00 price target.<\/p>\n

Wabash National (WNC)<\/strong>: DA Davidson maintained its Buy rating with a US$20.00 price target.<\/p>\n

Warner Bros. Discovery (WBD)<\/strong>: Morgan Stanley raised its price target to US$31.00 from US$29.00 while retaining an Equal Weight rating.<\/p>\n

West Pharmaceutical Services (WST)<\/strong>: Morgan Stanley upgraded the stock to Overweight and raised its price target to US$400.00 from US$365.00.<\/p>\n

Western Alliance Bancorporation (WAL)<\/strong>: Citigroup lowered its price target to US$95.00 from US$98.00 while retaining a Buy rating.<\/p>\n

Western Alliance Bancorporation (WAL)<\/strong>: Raymond James initiated coverage with an Outperform rating and a US$90.00 price target.<\/p>\n

Williams Companies (WMB)<\/strong>: Capital One Financial initiated coverage with an Overweight rating and a US$92.00 price target.<\/p>\n

Williams Companies (WMB)<\/strong>: Melius Research initiated coverage with a Buy rating and a US$84.00 price target.<\/p>\n

Xometry (XMTR)<\/strong>: Raymond James set a US$120.00 price target.<\/p>\n

Xometry (XMTR)<\/strong>: Rosenblatt Securities raised its price target to US$120.00 from US$110.00 while retaining a Buy rating.<\/p>\n

Yesway (YSWY)<\/strong>: William Blair initiated coverage with an Outperform rating.<\/p>\n

YETI (YETI)<\/strong>: Canaccord Genuity set a US$45.00 price target.<\/p>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Analyst Ratings (USA) The current analyst outlook remains cautiously positive, with positive recommendations accounting for most of today\u2019s coverage and upgrades continuing to outnumber…<\/p>\n","protected":false},"author":3,"featured_media":75145,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-75143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"\nAmerican Analyst Updates: Sept 22nd, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"American Analyst Updates: Sept 22nd, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings (USA) The current analyst outlook remains cautiously positive, with positive recommendations accounting for most of today\u2019s coverage and upgrades continuing to outnumber…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-22T21:21:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-23T04:12:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/09\/ChatGPT-Image-Sep-22-2026-05_16_47-PM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"American Analyst Updates: Sept 22nd, 2026\",\"datePublished\":\"2026-09-22T21:21:53+00:00\",\"dateModified\":\"2026-09-23T04:12:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/\"},\"wordCount\":2980,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News & Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/\",\"name\":\"American Analyst Updates: Sept 22nd, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-09-22T21:21:53+00:00\",\"dateModified\":\"2026-09-23T04:12:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"American Analyst Updates: Sept 22nd, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"American Analyst Updates: Sept 22nd, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/","og_locale":"en_US","og_type":"article","og_title":"American Analyst Updates: Sept 22nd, 2026","og_description":"Analyst Ratings (USA) The current analyst outlook remains cautiously positive, with positive recommendations accounting for most of today\u2019s coverage and upgrades continuing to outnumber…","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-09-22T21:21:53+00:00","article_modified_time":"2026-09-23T04:12:58+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/09\/ChatGPT-Image-Sep-22-2026-05_16_47-PM.png","type":"image\/png"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"American Analyst Updates: Sept 22nd, 2026","datePublished":"2026-09-22T21:21:53+00:00","dateModified":"2026-09-23T04:12:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/"},"wordCount":2980,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News & Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/","name":"American Analyst Updates: Sept 22nd, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-09-22T21:21:53+00:00","dateModified":"2026-09-23T04:12:58+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-sept-22nd-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"American Analyst Updates: Sept 22nd, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/75143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=75143"}],"version-history":[{"count":6,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/75143\/revisions"}],"predecessor-version":[{"id":75157,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/75143\/revisions\/75157"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/75145"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=75143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=75143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=75143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}